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Podocyte death and regeneration are major topics in kidney research but remain controversial. Data obtained in humans
demonstrate the existence of cells sited along Bowman’s capsule that behave as podocyte progenitors in vitro and in in vivomouse
models of podocyte injury xenotrasplanted with this human-derived population. However, this podocyte reservoir still remains
elusive inmurinemodels, where it could bemore easily studied. Transgenicmodels can be a powerful tool to identify this population
and to better understand its dynamics and hierarchies in both physiological and pathological conditions. Indeed, exploiting
transgenic approaches allows detecting, at the single cell level, movements, cell death, and replacement. Moreover, through lineage
tracing it is now possible to identify specific population increase and to point out clonal expansions during or after the regenerative
processes. However, applying transgenic strategies to study glomerular regeneration requires the search ofmarkers to unequivocally
identify this progenitor population. Achieving this aimwould lead to a deep comprehension of the biological processes that underlie
glomerular regeneration and clarify how different cell pools interface during this phase. Here we discuss strategies that have been
used and new approaches in transgenic models finalized to study podocyte loss and subsequent replacement.
1. Introduction
A crucial element of the nephron filtration barrier is a
specialized epithelial cell known as the podocyte. A vast
majority of renal diseases start with the dysfunction or loss
of podocytes, resulting in proteinuria that leads to nephron
degeneration and to kidney failure. No clinical methods are
actually available to heal podocyte damage, and the pro-
gressive loss of nephrons leads to failure of kidney function
and, finally, to end-stage renal disease (ESRD). Interestingly,
several studies have suggested that podocyte stem/progenitor
cells exist in humans providing a possible explanation for
the podocyte regeneration observed in several clinical and
experimental situations [1–3]. The existence of a progenitor
reservoir appointed to podocyte replacement has been clearly
demonstrated in other vertebrates like zebrafish [4–6]. On
the contrary, there are still conflicting opinions on the
notion of podocyte regeneration and supporting the identity
of the putative progenitor cells in the mouse. Given the
consequences of podocyte health for overall renal function, to
definitely elucidate the mechanism of podocyte regeneration
inmammals is of primary relevance. To this aim, the choice of
the most adequate model system and the correct interpreta-
tion of the data obtained from a specific model are the main
points that researchers must take into consideration. In the
last years, new methods that enable us to provide extremely
accurate data have been searched and developed. In par-
ticular, transgenic mouse models offer important tools for
research in the field of podocyte regeneration. For instance,
podocyte loss is the trigger stimulus in the chain of events
that lead to podocyte regeneration, and now temporally and
spatially regulated genetic systems for podocytes ablation are
available and allow researchers to strictly control podocyte
death. In addition, inducible mousemodels of lineage tracing
enable us to follow the events of regeneration in real-time by
labeling a specific cell type and tracking its fate. In this review,
we provide an introduction to transgenic mouse models, an
overview of transgenic mouse systems to induce podocyte-
specific cell death, discuss how transgenicmouse studies have
been used to evaluate podocyte regeneration, and how new
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transgenic strategies might help researchers in definitively
addressing mechanisms of podocyte regeneration.
2. Introduction to Transgenic Models
In the last decades, transgenic animals have been inten-
sively developed and used in order to understand how a
determinate gene deletion in a specific cell type correlates
with a particular phenotype, which is the role of a certain
gene in organ development, or which is the response of
organ-specific stem cells to a particular kind of injury [7–9].
Moreover, in transgenic models it is possible to mark certain
cell populations, study them at different time points, follow a
specific cell pool to understand its role during regeneration,
and exploit other benefits that will be discussed in this review.
In the past years, a big setback related to the creation of
transgenic animals has been the random genomic integration
of the foreign DNA (called transgene). This randomness
could result in loss of functionality of endogenous genes or
in the disconnection of a gene from the elements that control
its expression, leading to genetic deregulation that could alter
the physiological state of a cell. On the contrary, transgenes
may be inserted in chromosome sites that have been silenced,
thus resulting in low or complete loss of transgene expression
[7]. Nowadays it is possible to insert the exogenous DNA in
a specific locus of the animal genome thanks to a process
based on homologous recombination, called gene targeting.
By gene targeting it is thus possible to introduce, in the animal
genome, reporter transgenes which encode for markers that
can be used to identify, visualize, and track a desired cell type,
or different cellular populations, in pathological as well as in
physiological organ contexts.These reporters generally codify
for fluorescent proteins and are commonly inserted under the
Rosa26 locus by homologous recombination. To label a single
cell or to tag a specific population with a fluorophore, without
confusing this population with others, it is essential that the
genetic mechanisms that lead to the reporter expression are
controlled in a cell-specific manner. To achieve this aim,
cell-specific promoters, generally genes expressed only by
the population of interest, are engineered in order to induce
the expression of a recombinase enzyme. This enzyme, in
turn, will modify the DNA sequence of the reporter gene to
“unlock it” andmake it expressible.Themost common system
used for genetic recombination is the Cre recombinase-
LoxP system, in which Cre recombinase, expressed under
the control of a tissue- or cell-specific promoter, specifi-
cally activates the reporter expression by excising the Stop
sequence flanked by two LoxP sites (Figure 1(a)). If the Cre
recombinase recognizes two LoxP sites oriented in a head-
to-tail manner, it will remove the interposed (called “floxed”)
sequence, while rejoining the ends together. Otherwise, if
the LoxP sites are oriented in a head-to-head manner, the
interposed sequence will be simply inverted by the enzyme
[10–13]. Cre recombinase is widely employed to tag stem
cell populations of various organs and to discern them from
other cell pools [8, 14, 15]. Notably, its use combined with
the mT/mG (membrane-Tomato/membrane-Green) reporter
transgene enables us to identify cells that have undergone
genetic recombination. Indeed, this system allows us to track
a switch from a constitutive expression of the red fluorescent
protein tomato red, encoded in a cassette floxed by two
LoxP sites, to the expression of the downstream GFP (green
fluorescent protein) gene (Figure 1(b)).
The use of reporter transgenes has gained a pivotal role
and an increasing relevance in a very important tool for in
vivo experiments focused on regeneration: lineage tracing
analysis. Lineage tracing is defined as the possibility to tag
a single desired cell with a reporter and to identify all the
progeny derived from this cell. Since the irreversible DNA
modification that leads to the expression of the reporter is
inherited by all the daughter cells, it is possible to quantify
the progeny of a definite founder cell and follow its daughters’
behavior in physiologic as well as pathologic conditions
[10]. However, lineage tracing analysis is based on a fur-
ther evolution of transgenic models, the so-called inducible
models, which enable a time-based regulation of the Cre
recombinase activity. Indeed, in the conditional approaches
described above, genetic tracing labels all the cells that, in
any moment of their life, activated the cell-specific promoter
driving Cre expression. This in vivo genetic fate mapping
is frequently confused with lineage tracing analysis and
can give controversial results. For instance, upregulation or
transient activation of the chosen cell-specific promoters in a
different or unexpected cell population can lead to erroneous
experimental result interpretation. In inducible models, cell-
specific promoters induce Cre activity only as a consequence
of the administration of exogenous molecules that act as
inductors, as in the Tamoxifen-regulated system (CreERT) or
in the Tetracycline-regulated system (Figures 1(c) and 1(d),
resp.). Thus, the desired cell pool is tagged only during the
administration window of the inductor molecule, making it
impossible for a cell to undergo genetic recombination upon
withdrawal of the molecule, even if promoter-positive.
The introduction, in the last years, of multicolor reporter
constructs has increased the data output from tracing anal-
ysis. Of particular interest, Livet et al. developed a system,
called Confetti [13], that was extensively used to better
understand stem cells dynamics during regeneration, to dis-
criminate different cell types contribution in the repair phase
and to evidence clonal expansion [14, 16, 17]. This reporter
enables the expression of one out of four fluorescent proteins,
in a stochastic manner, by using alternating incompatible
LoxP variants (LoxP and pLox) and by linking reporter genes
in tandem with opposite DNA orientation in between these
LoxP sites. These variants give rise to mutually exclusive
excision of fluorescent reporters, thus inducing the cell to
randomly acquire one out of four colors [13] (Figure 2).
TheConfetti reporter not only enables the examination of
the individual behavior ofmultiple stem cells in a single niche
but also allows us to study how different positional effects
in the niche can affect differentiation of stem or progenitor
cells [16, 17]. Moreover, the randomness of the recombination
events and the possibility to tag cells with different fluo-
rophores allow us to easily visualize clonal expansion of single
cells that will appear as continuous clusters of cells of the
same color. Cellular hierarchies can thereby be resolved with
high definition, without confounding progenitors with cells
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Figure 1: Schematic representation of the principal transgenic solutions. Each line represents a mouse strain, which is crossed with other
transgenic strains in order to obtain double or triple transgenic animals. (a) Cell-specific promoter directly controls Cre activity creating a
constitutive model. When the promoter gets activated Cre recombinase will be expressed and will gain access to LoxP sites. By removing
the LoxP-floxed Stop cassette, the recombinatorial event will lead to GFP expression. (b) mT/mG (membrane-Tomato/membrane-Green)
reporter construct in a constitutive scheme.The cell-specific promoter, in this setting, will change desired population color from ubiquitously
expressed tomato red protein to GFP, evidencing cells that had recombinatorial activity. (c) Inducible model based on a fused form of Cre
recombinase and estrogen receptor (ERT) proteins. If the chosen promoter is activated this fused protein will always be transcribed. Only
following Tamoxifen treatment the ERT will bind the inductor and enter the nucleus, where Cre recombinase will act on the LoxP site of the
reporter transgenemT/mG. (d) Induciblemodel based on reverse Tetracycline-controlled transactivator (rtTA) protein, which is continuously
created by the activated specific promoter. When bound to Tetracycline (Doxycycline form), the transcriptional factor is able to activate Cre
transcription controlled by TetO operator sequences. (e) Imaged glomeruli in a podocyte-driven mT/mG setting prior to (left panel) and
following (right panel) induction. The strong fluorescence signal of this reporter line enables the visualization of podocyte primary foot
processes (right enlarged box).
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Figure 2: Schematic overview of the Confetti reporter system. In the center, the whole construct. On the bottom, excision eliminates reporter
gene thus turning on one cell color. On the top, inversions rely on pLox sites that are used to invert the construct favoring other colors (Cre
recombinase inverts segments floxed between two LoxP sites oriented in a head-to-head fashion). Both inverted and excised fragments can
continue to invert as long as there is Cre activity, since LoxP sites are excised, while pLox sites are not. Consequently, an inducible model
might be best suitable to stabilize cell color following inductor molecule removal. All recombinatorial events that do not involve the LoxP site
upstream to the Stop cassette would result in no color acquisition by the cell.
under transient state changes (i.e., dedifferentiation), which
complicate accurate cellular identification by antibody-based
methods.
All these discussions evidenced how much transgenic
strategies would be useful in deciphering regenerative routes.
In the following sections, we will focus on transgenic tactics
to induce podocyte loss and, consequently, evaluate their de
novo generation.
3. Podocyte Ablation: Transgenic Strategies to
Induce Podocyte Loss
The major question related to glomerular regeneration is
centered on the podocyte, a cell with an extremely complex
cytoskeleton that composes the glomerular filtration barrier
and which is the target of a broad range of chemical and
physical insults. Indeed, podocytes react to immune- and
nonimmune-mediated injury with rearrangement of the
complex actin cytoskeleton, spreading of the foot processes
along the GBM (glomerular basement membrane), loss of
filtration slits, and apical redistribution of slit diaphragm
proteins. Consequently, a progressive reduction in podocyte
number from podocyte death and/or detachment is observed
and leads to the development of glomerulosclerosis, the
pathological basis of chronic renal failure. In human, evi-
dence demonstrated that a population of cells localized
in the parietal epithelium of Bowman’s capsule possesses
characteristics of stem/progenitor cells. This population can
be expanded as clones in culture and can differentiate into
podocyte both in vitro and in vivo following intravenous
administration in a SCID (severe combined immunodefi-
ciency) mice model affected by adriamycin nephropathy
(AN), the experimental analogous of human focal segmental
glomerulosclerosis (FSGS) [1, 2]. However, the existence of
this population in mouse is still an open question whose
answer is of paramount importance in regenerative nephrol-
ogy research. Indeed, a greater understanding of podocyte
biology and of the regenerative role of renal progenitors
may provide novel therapeutics to treat glomerular disease.
Any attempt to identify a progenitor pool able to regenerate
lost podocytes relies on experimental procedures to induce
podocyte loss. In humans, podocyte damage is the starting
event leading to FSGS, a disease histologically characterized
by the presence of sclerosis of part of the glomerular capillar-
ies in aminority of glomeruli. Clinically, podocyte loss results
in proteinuria, hypoalbuminemia, hypercholesterolemia, and
peripheral edema, that is, nephrotic syndrome. FSGS is not a
single disease but a lesion as a result of different pathophysi-
ologies that cannot be recapitulated by a single animalmodel.
Thus, different animalmodels of both primary and secondary
FSGS, with specific pros and cons, have been developed
to mimic the clinical pathological features of human FSGS
[18, 19]. The choice of the model most appropriate to the
experimental purpose must be guided by the question that
the researcher is trying to solve. In this review we will focus
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our attention on models of FSGS obtained using transgenic
mice. However, we will provide also a brief description of
the twomost widely used nontransgenicmodels: the remnant
kidney and adriamycin nephropathy. In the remnant kidney
model, 4/6 or 5/6 of the total renal mass is surgically removed
by unilateral nephrectomy coupled to ligation of renal artery
branches or polectomies in the contralateral kidney. These
surgical procedures lead to hypertension, renal damage, and
FSGS (which is more severe in the 5/6 model). The remnant
kidney model is mainly used in rats. Indeed, the anatomic
distribution of the renal artery branches makes it difficult to
achieve reproducible 5/6 nephrectomy in mouse; moreover,
while 5/6 nephrectomy may be sufficient to evoke develop-
ment of FSGS in 129/Sv male mice within 1-2 months, most
mouse strains, including the C57Bl/6 strain, are resistant
to this procedure and do not develop FSGS [20, 21]. In
C57Bl/6 mice, it is necessary to treat 5/6 nephrectomized
animals with deoxycorticosterone acetate (DOCA) and a
high salt diet to induce FSGS. These procedures result in
hypertension and nephrosclerosis (an endocrine hyperten-
sion model). However, like for the remnant kidney model,
the degree of hypertension and hypertensive renal lesions is
markedly different between variousmouse strains commonly
used in research, with 129/Sv strain more susceptible than
C57Bl/6 [22]. Surprisingly, in this mouse model, the amount
of albumin excretion did not correspond to the degree of
glomerular damage and therefore albuminuria is not a good
predictor for the degree of glomerular scarring, making the
screening of kidney injury for treated mice more challenging
[22].
FSGS can also be induced by treating animals with
podocyte-toxic drugs, such as adriamycin (Pfizer, Sydney,
Australia) (doxorubicin). After the initial toxic injury, mice
develop an immune-mediated chronic proteinuric renal dis-
ease. The clinic pathological features of AN are nephrotic
syndrome, focal glomerulosclerosis, tubular injury, and inter-
stitial compartment expansion with infiltration of mononu-
clear cells that are composed largely of macrophages and T
cells. In mice, AN is associated with acceptable mortality
(less than 5%) andmorbidity (weight loss) [18]. Nevertheless,
several critical points must be taken into consideration when
performing adriamycin nephropathy experiments. As first
issue, the identification of the optimal regimen of adriamycin
administration requires great effort because of the variability
between species, strain, gender, and age of the animals and
even differences between animals of the same litter. Most
rat species are completely sensitive to the renal effects of
adriamycin. In male Wistar rats, the dose of adriamycin
ranges between 1.5 and 7.5mg/kg. Instead, male BALB/c mice
require 9.8–10.4mg/kg, [23] while male SCID mice devel-
oped on a BALB/c background require only 5.3mg/kg [24].
C57Bl/6 mice are highly resistant to adriamycin-induced
renal injury, but renal injury may be inducible at higher
doses (13–25mg/kg) than those required for BALB/c mice
[25–27]. In C57Bl/6-based models, while most studies use
a single injection, regimens using multiple injections (i.e.,
2mg/kg × 2 in 20 days, 1mg/kg/day × 7 days, and 2.5mg/kg
× 6 in 14 days) have also been reported. The choice of the
effective dose is further complicated by the variability among
drug sources and batches. To overcome these problems, dose-
finding tests are usually necessary to ascertain the exact dose
necessary to induce the pathological changes required by the
investigator. Finally, adriamycin has also effects that are not
specific to the kidney such as myelotoxicity, hepatotoxicity,
cardiomyopathy, and neurotoxicity as evidenced by lack of
animal coordination [18, 28].
Although AN and remnant kidney models both resem-
ble human FSGS, adriamycin nephropathy, which induces
podocyte oxidative stress, fostered the concept of pri-
mary podocyte injury in the pathogenesis of foot process
effacement and glomerulosclerosis. By contrast, renal abla-
tion models pointed to glomerular hypertension (elevated
glomerular capillary pressures and flow rates) as the primary
pathophysiologic process in the course of adaptive responses
to reduced number of functioning nephrons, in turn causing
secondary podocyte injury [29, 30].
Advances in transgenic and gene-targeting technologies
have elucidated the function of individual genes in glomeru-
lar health and disease. Several animal models are now avail-
able, in which a transgene insertion or the modification of a
gene in podocytes leads to a more or less severe albuminuria,
sometimes of nephrotic range, and focal glomerulosclerosis
[31–34]. However, conditional cell-targeted ablation consti-
tutes the most promising genetic tool to analyze cell lineage
relationships, the role of specific cells during embryogenesis,
or physiological processes. Moreover, the ability to control
temporally and spatially the tissue damage and to genetically
remove a specific cell population has important applications
for regeneration studies. The ideal genetic cell ablation tool
must be (1) spatially controllable and strictly confined to
the target cell population, (2) temporally inducible, (3)
germline transmissible, and (4) reversible. In this paragraph
we will focus our attention on three of the most commonly
used transgenic models in which genetically controlled cell
removal ensures the highest precision and consistency in
studying the consequences of podocyte damage. As a conse-
quence, studies onmechanisms of podocyte regeneration can
be more accurately performed.
Thy-1.1 Model. In their endeavor to study the function of the
Thy-1 antigen, Kollias et al. [35] generated transgenic mice
that ectopically express a mouse-human chimeric Thy-1.1
antigen. Some of these transgenic mice expressed the Thy-1.1
antigen specifically on podocytes, slowly and spontaneously
developing albuminuria (from week 7 onward) and focal
glomerulosclerosis [35, 36]. After podocyte-specific strain
isolation, the model has been extensively used in experimen-
tal settings based on the anti-Thy-1.1 monoclonal antibody
(mAb) injection. mAb administration induced an acute albu-
minuria in nonalbuminuric, 5-week-old Thy-1.1 transgenic
mice, while the same procedure did not cause albuminuria in
nontransgenic mice [36]. Smeets et al. described in detail the
dose-dependent effects of anti-Thy-1.1 mAb treatment [37]:
high dose injection (1000mg) induces an albuminuria within
10min that persisted over a 3-week period. With lower doses
(100 𝜇g) of anti-Thy-1.1 mAb, on the contrary, the developed
albuminuria rapidly dropped and returned to baseline levels
within 7 days. Glomeruli became increasingly ischemic with
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no sign of podocytic hypertrophy or swelling. Electron
microscopy revealed reduction in number of foot processes
and decrease in diameter of slit pores already 10 minutes
after mAb injection, while no large gaps between podocytes
or podocyte detachment were observed [37]. In this respect,
this model closely resembles human nephropathies such as
minimal change disease or FSGS. In contrast to adriamycin
that causes severe podocytic injury leading to necrosis and
detachment of the podocytes from the GBM, in this model,
the podocyte injury is relatively small, with no detachment
detectable in the first 24 h after mAb administration. More-
over, in AN the level of proteinuria correlates with the degree
of podocyte detachment, while in the anti-Thy-1.1 model
podocyte injury is relatively minor despite massive protein-
uria. Actually no Rosa26 targetedThy-1.1 mice line exists that
can be exploited with the Cre-LoxP strategy, thus hampering
the possibility to specifically control transgene expression by
using constitutive or inducible podocyte-specific promoters.
NEP25 Model. This model relies on an immunotoxin-
mediated cell targeting technology. LMB2 is a chimeric
protein composed of the Fv portion of an anti-Tac (human
CD25) antibody and PE38, a mutant form of Pseudomonas
exotoxin that contains the translocation and ADP ribosyla-
tion domains. LMB2 has been used to ablate specific cell types
in transgenic mice that express hCD25 in the target cells [38,
39]. Transgenic mouse lines that express hCD25 selectively
in podocytes, as the one directed by the nephrin promoter,
have been successively developed [40]. Two to three days
after LMB2 injection these mice developed nonselective pro-
teinuria, hypoproteinemia, ascites, edema, and renal failure.
Because of severe edema and/or renal failure,most transgenic
mice died at a time inversely related to the dose of LMB2
injected. With 0.625 ng/g body weight of the toxin, the
majority of the transgenic mice showed mild and transient
ascites and survived for more than 28 days. Proteinuria
peaked at the seventh day and, thereafter, gradually decreased
with time, returning nearly to the normal range within
28 days [40]. Light microscopy, transmission and scanning
electron microscopy, and immunostaining for podocyte
marker proteins demonstrated damage and progressive loss
of podocytes, but transferase-mediated dUTPnick-end label-
ing detected only rare apoptosis in the glomerulus indicating
that apoptosis is not the major mechanism of the podocyte
loss [41]. In addition to podocytes, glomerular endothelial
cells, mesangial cells, parietal epithelial cells (PECs), and,
later, tubular cells became damaged. Mice that survived for
more than 3 weeks developed segmental or global glomerular
sclerosis. It is interesting that, 4 weeks after LMB2 injec-
tion of 0.625 ng/g per body weight, the average scores of
epithelial injury and mesangial changes were better than
those measured at 3 weeks after the damage onset [40]. In
addition, urinary protein was almost in normal range 4weeks
after the toxin administration. These suggest that glomeruli
that are only mildly injured by LMB2 have the ability to
recover.The advantages of thismodel are that transgenicmice
are completely normal unless they receive LMB2 treatment,
facilitating colony maintenance and reproduction. Moreover,
the damage severity is dose-dependent and controlled by
LMB2 quantity injection.
DTRModel. The A chain of diphtheria toxin (DTA) catalyzes
the ADP-ribosylation of the eukaryotic elongation factor 2,
resulting in inhibition of translation, which finally leads to
cell death [42, 43]. However, rodents are resistant to DTA
because rodent heparin-binding epidermal growth factor-
like growth factor does not bind the toxin. On the contrary,
the forced expression of the human DT receptor (DTR)
in a target cell population is able to render mouse cells
susceptible to the toxin effects, triggering cell death [44].
Alternatively, it is possible to induce endogenous expression
of DTA in the target cell, as proposed by Breitman et al.
[45] and Palmiter et al. [46]. Recently, a conditional mouse
line in which the expression of DTA can be controlled by
Cre recombinase activity has been generated, thus allowing
widespread ablation of different cell types by the use of tissue
specific Cre-lines. Lately, Brockschnieder et al. described a
mouse line in which a LoxP conditional DTA allele was
introduced into the ubiquitously expressedRosa26 locus [47].
Wharram et al. successfully used this strategy to study the
pathological consequences of podocyte injury in adult rats
[48], evidencing mesangial matrix expansion, formation of
synechiae, and development of sclerosis areas with collapse
of glomerular capillaries. Analogously, Jia et al. described
a mouse podocyte ablation model in which the podocin
(NPHS2) promoter directs Cre-mediated DTA176 (an atten-
uated DTA gene) production and subsequent podocyte abla-
tion during nephrogenesis [49]. What renders this model so
interesting is that in vitro studies suggest that internalization
of as little as a single molecule causes a cell to die [50].
Recently, a Cre-inducible transgenic mouse strain, in which
a LoxP-flanked Stop cassette and the simian diphtheria toxin
receptor (iDTR) gene were targeted under the Rosa26 locus
of mouse genome, has been generated (iDTR mouse) [51]
(Figure 3(a)). iDTR mice can be crossed with any kind of
Cre recombinase-expressing mice in which the enzyme is
active only in a specific cell pool due to cell-specific promoter
activation. Wanner et al. [52] crossed the iDTR strain to
hNPHS2.rtTA, TetO.Cre, and mT/mG mice to specifically
target podocyte ablation, in a dose-dependent manner, and
determine the influence of acute podocyte loss on podocyte
regeneration (Figure 3(b)). High doses (25–100 ng/g body
weight) of DT resulted in massive albuminuria and loss of
nearly all podocytes, whereas lower doses (2 and 5 ng/g body
weight) were sufficient to cause a net loss of approximately
12% of all podocytes after 4 weeks, without imposing any
persistent gross damage to the tissue. This injury led to a
transient increase in albuminuria, which gradually decreased
over 28 days [52].
The strength of the NEP25 and DTR models is that,
by targeting specific cell populations, they show no obvious
gender differences, as what happens in AN-based models,
and that pathological and morphological changes can be
modulated simply by adjusting the drug dose. The intrinsic
limit of these models is that they cause specific but acute
podocyte ablation, which is optimal to study podocyte de
novo creation, but it does not closely resemble the vast
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Figure 3: DTR models and strategies. (a) Schematic representation of a floxed Stop cassette followed by DTR transgene targeted under the
Rosa26 promoter.The reporter transgene, activated uponCre recombinase activity induced by podocin promoter activation, forces podocytes
to express the DT receptor. The operator can thus easily induce podocyte cell death in a time- and dose-controlled manner. (b) Quadruple
transgenic hNPHS2.rtTa; TetO.Cre;mT/mG; iDTR, in which podocytes can be prompted to turn from red to green while expressing the DTR.
Once induced, the authors provoked podocyte death through DT injection [52].
majority of human podocyte-related pathologies, in which
podocyte loss is a long-standing and progressive event.
In conclusion, several goodmodels that recapitulate FSGS
are available; nevertheless, choosing the correct model to
address specific hypothesis is the essential prerequisite for the
success of research.
4. Podocyte Regeneration:
Transgenic Tactics to Identify Progenitor
Pool for Podocyte Replacement
Transgenic models have been widely employed, in the last
ten years, to identify stem or progenitor populations present
in the glomerular compartment and to understand their role
in podocyte turnover in both homeostasis and pathological
states. One of the first groups that used genetic strategies to
identify podocyte reservoir has been Moeller’s group that, in
2009, using a fused form of human and rabbit podocalyxin as
promoter, tagged parietal epithelial cells of Bowman’s capsule
[53], already described in humans as podocyte progenitors
[2]. By employing this inducible mouse model, the authors
were able to specifically label mature PECs with 𝛽-gal,
allowing the direct visualization of this compartment for
the first time in rodents [53]. This intriguing strategy that
later was found to be essential for the discovery of PEC
pathological participation in glomerular sclerotic lesions and
in crescent formation [54, 55] allowed us to show that PECs
labeled at postnatal day 5 migrated to the glomerular tuft and
differentiated into podocytes, providing evidence, confirmed
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also byWanner et al., that some podocytes are recruited from
PECs at least in juvenile mice [52, 53]. In a more recent
paper, the same group confirmed that, during adolescence,
generation of podocytes occurs from a subpopulation of
PECs that the authors called “podocyte reserve,” that is, cells
already committed to become podocytes, which shows a
transitional phenotype and can be found in Bowman’s capsule
only in juvenile mice and not in adult mice [56]. Using
the same lineage tracing model, podocyte generation from
PECs could not be detected in aging mice or in models
of glomerular hypertrophy (5/6 nephrectomy and DOCA-
salt model) [56]. It is reported that stem/progenitor cells
participate not only in regenerative response to acute injury
but also in the general maintenance function of replacing
cells that are lost during physiologic organ activity, that is,
homeostasis. However, some tissues such asmuscle and brain
exhibit limited turnover. The finding on aging reported by
Berger et al. [56] and confirmed also by Wanner et al. [52]
suggests that this is true also for the kidney: podocytes
have long lifespan and are rarely replaced. It is possible
that the aging process in the glomerulus is accompanied by
subtle and gradual effects that are compensated during time
mostly by nephron surplus [57] and podocyte hypertrophy
[57, 58] and thus do not involve the putative progenitor
compartment. Interestingly, even in the liver, a tissue with a
dramatic regenerative capacity, stem cells are not used during
homeostasis but are called into service only upon injury
[59, 60]. However, Berger et al. fail to evidence a role for
PECs even after injury using twomodels of glomerular hyper-
trophy. Indeed, they observed that PECs participate only
in the formation of sclerotic lesions, whereas hypertrophied
glomeruli did not showmigration of genetically tagged PECs
to the glomerular tuft, thus arguing against the role of PEC in
podocyte regeneration [56]. However, a questionable point in
the papers from Appel et al. [53] and from Berger et al. [56]
remains the promoter used to tag putative progenitors: can
the fused form of human and rabbit podocalyxin genes be
used as a promoter to correctly identify progenitor cells?
In a recent paper, Hackl et al. [61], employed a consti-
tutive transgenic mice model controlled by the rat phos-
phoenolpyruvate carboxykinase promoter (PEPCK), crossed
with a GFP reporter strain, to genetically tag PECs. The
authors, using a unilateral ureteral obstruction (UUO) dis-
ease model, evidenced rare GFP-positive PECs that migrated
from Bowman’s capsule vascular pole to the glomerular tuft.
Nevertheless, this constitutive model does not allow us to
unequivocally identify the progenitor pool because of the
nonspecificity of the used promoters, which did not mark all
PECs, while tagging also other pools [61] with a high grade of
recombination in S1–S3 proximal tubular cells [62].
Sakamoto et al. [63] used a constitutive transgenic mouse
expressing 𝛽-gal and human CD25 under the control of
the nephrin promoter, allowing tagging of podocytes as to
induce their specific ablation by LMB2 injection. Follow-
ing podocyte ablation, the authors investigated phenotypic
transition from podocyte to PECs or vice versa by double
staining for podocyte or PEC markers. The conclusion is
that podocytes undergo epithelial phenotypic transition into
PEC [63]. However, by this transgenic tactic, they performed
a genetic fate mapping of podocyte pool and are not tracing
the podocyte lineage cell since any cell that might have
expressed nephrin, at any moment and even for a very
short period, would result as 𝛽-gal+. Thus, 𝛽-gal+ cells could
result not only fromnephrin expression in fully differentiated
podocytes but also from progenitors starting to acquire
this podocyte markers upon differentiation into podocyte
lineage, as already reported in human [2] and rodents [53]
studies of two different groups. This is further corroborated
by the findings that, in the paper [63], claudin+ WT1+
cells were reported to mainly localize at the vascular pole,
sustaining the idea of PEC differentiation to podocyte while
migrating to cover the tuft along the denuded glomerular
basement membrane. Furthermore, identification of cells by
immunostaining for specific protein markers can lead to
misinterpretation of results due to upregulation ofmarkers as
consequence of damage or as response to injury, also in more
than one particular cell type.
A different hypothesis related to podocyte regeneration
has been recently formulated by Pippin et al. who lineage-
traced the cells of the juxtaglomerular apparatus by engi-
neering the mouse genome with a modified and inducible
form, of the renin gene [64]. The authors were thus able to
show that renin-positive cells possess regenerative capacities
because of their ability to substitute, in an experimental
model of FSGS, not only lost podocytes but also PECs. This
suggests that cells of renin lineage may have the capacity to
serve as upstream progenitors for both PECs and podocytes
[64]. However, this population localizes in the preglomerular
vascular wall, and it is actually unclear how it would cross
the parietal and the glomerular basement membrane to
gain access to the glomerular compartment [65]. Moreover,
the number of podocytes generated by renin expressing
cells appeared extremely low and its relationship with the
outcome of the disease has not been definitively proven. A
subsequent study of the same group focused on the role
of renin-positive cells in aging nephropathy [66], which is
characterized by progressive podocyte loss and consequent
focal and global glomerulosclerosis [67, 68]. In the paper, the
authors used a constitutive model in which the renin gene
drives the recombination that leads to ZsGreen fluorophore
expression.Thanks to this genetic fatemapping, it was proved
that, at 1 year of age, the intraglomerular compartment
exhibited an increment in the number of cells of renin lineage,
most of which expressed markers exclusively associated with
differentiated podocytes (as podocin and synaptopodin) [66].
However, in this genetic fate mapping strategy based on a
constitutive model is not possible to understand if the renin-
positive pool can substitute lost podocytes, since any cell
(and also podocytes [69, 70]) that had expressed renin, in
any moment of the animal life, would be tagged by the
reporter. The study by Starke et al. further challenged the
involvement of cells of renin lineage in podocyte turnover
with an inducible model that enabled tagging of the renin+
population with 𝛽-gal reporter transgene [71]. By setting
up a mesangial injury in this transgenic model the authors
proved that renin descendant cells never colocalized with
podocyte or PEC markers, denying their role as podocyte
or even PEC reservoir, evidencing instead a prominent role
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Figure 4: Hypothetical scheme of a combinatorial solution for PEC tagging and podocyte-specific ablation. (a) Glomerulus before induction
of the two recombinatorial systems (Cre-LoxP and Flp-FRT), which can be induced independently and at different time points. (b) Once
induced, the glomerulus would appear with Confetti-tagged PECs and iDTR-expressing podocytes. (c) At the prespecified time and dose, the
operator could specifically ablate only podocytes. (d) De novo podocyte generation by the PEC compartment.
in intraglomerular mesangial cell substitution [71]. Thus,
controversial findings in the literature still leave the role of
renin-positive cells as podocyte progenitors undefined.
A recent and very elegant paper by Wanner et al.
demonstrated how transgenic animals can be used to study
glomerular regeneration and podocyte replacement in aging
nephropathy, in a unilateral nephrectomy model and follow-
ing acute podocyte loss [52]. To study podocyte regeneration
the authors induced a severe podocyte depletion thanks to
the mentioned transgenic tactics of specific ablation of cells
engineered to express the iDTR transgene. To this aim, they
created a quadruple inducible transgenic mouse governed by
the podocin promoter, which in turn acts on the mT/mG
transgene targeted under one Rosa26 allele and on the iDTR
transgene inserted in the other Rosa26 allele. To develop
this model, Wanner et al. created two different transgenic
lines, both governed by podocin promoter, but with two
different reporter transgenes (iDTR in one line and mT/mG
in the other one). When crossed, these lines gave rise to
the quadruple transgenic model, with one Rosa26 allele
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leading to iDTR expression and with the other Rosa26 allele
carrying the mT/mG transgene (Figure 3(b)). This strategy
enabled tagging of podocytes with GFP, while inducing iDTR
expression and thus rendering the cells susceptible to toxin-
induced ablation. By this it was possible to visualize and
quantify by flow cytometry de novo generated podocytes,
since they can only be red-colored due to the withdrawal of
Doxycycline before the onset of the damage. This transgenic
route presents intrinsic limits since it is not possible to
identify the source of novel podocytes or to individuate
progenitor population origin [52]. Intriguingly, a month after
DT injection, the authors reported that about 38% of lost
podocytes are replaced by newly generated Tomato Red+
podocytes. On the contrary, neither in the aging nephropathy
model nor in the unilateral nephrectomy setting, an increase
in Tomato Red+ podocytes was evidenced [52]. Data on
the aging model have been already discussed above. Sim-
ilar consideration can be made to explain why podocyte
regeneration observed in the iDTRmodel cannot however be
highlighted in the unilateral nephrectomy model, in which
the major compensatory mechanism to the nephron loss is
the hypertrophy of the survived glomeruli [52, 56]. However,
even in the 5/6 nephrectomy and 5/6 nephrectomy + DOCA
salt, Berger et al. did not observe podocyte regeneration [56].
In conclusion, from the available experimental data on
transgenic mouse models, we can state that cells located in
Bowman’s capsule give rise to podocytes during the first
weeks of age.
The role of PECs or other podocyte progenitors following
injury is however still a matter of debate, with discrepancies
among studies even on the possibility that podocyte regener-
ation may occur at all. What account for these discrepancies?
One explanation is related to the fact that the renal progenitor
cell activity may be more or less marked depending on the
nature of injury, as described in liver stem cells [60], or
depending on the magnitude of the damage. It is well known
that elevated albuminuria impairs PEC differentiation into
podocytes, as demonstrated by Peired et al. [72]. It is thus
possible that podocyte regeneration could be visualized only
in models in which regression of glomerular damage occurs.
To this aim, specific podocyte ablation models are more
suitable because the degree of podocyte loss could be more
finely modulated [48]. In agreement with this hypothesis is
the finding that, using the iDTRmodel,Wanner et al. provide
evidence for podocyte regeneration when animals received a
DT dose sufficient to cause a net loss of approximately 12%
of all podocytes but without imposing any persistent gross
damage to the tissue [52].
In addition, all the studies reviewed here evidence the
necessity to find a PEC-specific promoter physiologically
expressed only in this cell type. This will pave the way
for further evolution of transgenic tactics finalized to a
deep comprehension of the dynamics between PECs and
podocytes. In this context, an important aim would be the
creation of a multiple combinatorial inducible transgenic
model in which both PECs and podocytes are engineered, the
first with a fluorescent reporter and the second with a con-
struct for cell ablation. A possible solution, for instance, could
be the development of a Confetti-marked PECs, controlled by
the Cre-LoxP system, combined to podocyte-targeted iDTR
transgene expression controlled by the flippase recombinase
that recognizes flippase recognition target (FRT) (FLp-FRT
system) (Figure 4). The creation of a hypothetical transgenic
model like this would require great efforts, but similar com-
binatorial tactics are actually under development in various
organisms and organ system and hold great promises for
regenerative studies [73, 74].
5. Conclusions
Transgenic animal models, recombinatorial strategies, and
related lineage tracing analysis are powerful tools that can
be widely applied to understand the mechanisms that govern
kidney dynamics and regeneration. Transgenic approaches
are not only changing our views on kidney regeneration
capabilities but also opening to researchers new perspectives
in various aspects of kidney physiology that will grant great
advantages in understanding this complex organ. Notwith-
standing, transgenic-related techniques still need a further
development in order to unequivocally identify and charac-
terize stem and progenitor populations involved in podocyte
replacement.
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